In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...

GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...

The Federal Trade Commission has filed a lawsuit to block private equity firm GTCR BC Holdings from acquiring Surmodics, a medical technology company, arguing the deal would reduce competition for ...

The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...

The Federal Trade Commission under President Trump is making its first move to challenge private equity in health care, by ...

Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...

Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

The Federal Trade Commission sued Thursday to block private equity firm GTCR BC Holdings’ acquisition of Surmodics Inc., ...

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...

The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.